[EN] CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES<br/>[FR] INHIBITEURS HYDRAZINO CARBOCYCLIQUES DES AMINE OXYDASES A TENEUR EN CUIVRE
申请人:BIOTIE THERAPIES CORP
公开号:WO2003006003A1
公开(公告)日:2003-01-23
The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R?1 to R11¿ are as defined herein.
本发明涉及碳环肼类化合物,作为含铜胺氧化酶(常称为半卡巴肼敏感的胺氧化酶(SSAO))的抑制剂,包括人类SSAO,即血管粘附蛋白-1(VAP-1)。这些SSAO抑制剂具有治疗作用,可用作药物治疗包括但不限于多种炎症状况和疾病(尤其是慢性炎症状况,如慢性关节炎、炎症性肠病和慢性皮肤病)、与碳水化合物代谢和脂肪细胞分化或功能异常以及平滑肌细胞功能相关的疾病以及血管疾病。新型化合物的一般式为:或其药学上可接受的溶剂、水合物或盐,其中R?1到R11?如本文所定义。